Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-08
1996-06-18
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546144, 546147, A01N 4342, C07D21700
Patent
active
055278108
ABSTRACT:
This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines.
REFERENCES:
patent: 4902695 (1990-02-01), Ornstein
patent: 5356902 (1994-10-01), Ornstein
Sheardown et al., "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: A Neuroprotectant for Cerebral Ischemia", Science, 247, 571 (1990).
Buchan et al., "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia", Neuroreport, 2, 473 (1991).
LePeillet et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat", Brain Research, 571, 115 (1992).
Ornstein et al., "Syntheses of 6-Oxodecahydro-isoquinoline-3-carboxylates. Useful Intermediates for the Preparation of Conformationally Defined Excitatory Amino Acid Antagonists", J. Org. Chem., 56, 4388 (1991).
Jacques, Collet, and Willen, "Enantiomers, Racemates and Resolutions", 253-259, John Wiley and Sons, N.Y., 1981.
Bullock and Fujisawa, "The Role of Glutamate Antagonists for the Treatment of CNS Injury", J. Neurotrama, 9 (Supp. 2), S443 (1992).
Scatton et al., "N-Methyl-D-Aspartate Receptor Antagonists: A Novel Therapeutic Perspective for the Treatment of Ischemic Brain Injury", Cerebrovascular Dis., 1, 121 (1991).
Bullock et al., "Focal Cerebral Ishcemia in the Cat: Pretreatment with a Competitive NMDA Receptor Antagonist, D-CPP-ene", J. Cerebral Blood Flow and Metabolism, 10, 668 (1990).
Simon and Shirasho, "N-Methyl-D-Aspartate Antagonist Reduces Stroke Size and Regional Glucose Metabolism", Annals of Neurology, 27, 606 (1990).
Madden et al., "Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia", J. of Neurosurgery, 76, 106 (1992).
Schoepp et al., "Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist", J. of Neural Transmission, 85, 131 (1991).
Meldrum, "Excitatory amino acids in epilepsy and potential novel therapies", Epilepsy Research, 12, 189 (1992).
Meldrum, "Excitatory Amino Acid Transmitters in Epilepsy", Epilepsia, 32 (Supp. 2) S1 (1991).
Chapman and Meldrum, "Excitatory amino acids in epilepsy and novel anti-epileptic drugs", New Antiepileptic Drugs, 39 (1991).
France, Winger, and Woods, "Analgesic, anesthetic, and respiratory effects of the competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys", Brain Research, 526, 355 (1990).
Murray, Cowan, and Larson, "Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model", Pain, 44, 179 (1991).
Covington Raymond
Eli Lilly and Company
Hay Martin A.
Ivy C. Warren
Leeds James P.
LandOfFree
Decahydroisoquinoline compounds as excitatory amino acid recepto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Decahydroisoquinoline compounds as excitatory amino acid recepto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Decahydroisoquinoline compounds as excitatory amino acid recepto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-223162